Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovasc… Read more
Hubei Jumpcan Pharmaceutical Co Ltd (600566) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.68 Billion CNY
Based on the latest financial reports, Hubei Jumpcan Pharmaceutical Co Ltd (600566) has total liabilities worth CN¥2.68 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hubei Jumpcan Pharmaceutical Co Ltd - Total Liabilities Trend (1998–2024)
This chart illustrates how Hubei Jumpcan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hubei Jumpcan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hubei Jumpcan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sandy Spring Bancorp Inc
NASDAQ:SASR
|
USA | $12.57 Billion |
|
Chengdu Xingrong Investment Co Ltd
SHE:000598
|
China | CN¥28.47 Billion |
|
Bitfarms Ltd
NASDAQ:BITF
|
USA | $189.92 Million |
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
|
China | CN¥2.44 Billion |
|
City Developments Ltd
PINK:CDEVY
|
USA | $16.03 Billion |
|
Ningbo Boway Alloy Material Co Ltd
SHG:601137
|
China | CN¥11.22 Billion |
|
Seaboard Corporation
NYSE MKT:SEB
|
USA | $3.01 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Jumpcan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Jumpcan Pharmaceutical Co Ltd (1998–2024)
The table below shows the annual total liabilities of Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.73 Billion | -21.82% |
| 2023-12-31 | CN¥4.77 Billion | +31.59% |
| 2022-12-31 | CN¥3.63 Billion | +20.96% |
| 2021-12-31 | CN¥3.00 Billion | +8.99% |
| 2020-12-31 | CN¥2.75 Billion | +7.52% |
| 2019-12-31 | CN¥2.56 Billion | +9.43% |
| 2018-12-31 | CN¥2.34 Billion | +3.48% |
| 2017-12-31 | CN¥2.26 Billion | +73.89% |
| 2016-12-31 | CN¥1.30 Billion | +48.99% |
| 2015-12-31 | CN¥872.59 Million | -17.97% |
| 2014-12-31 | CN¥1.06 Billion | +23.40% |
| 2013-12-31 | CN¥862.04 Million | +71.70% |
| 2012-12-31 | CN¥502.07 Million | +15.42% |
| 2011-12-31 | CN¥435.00 Million | +26.86% |
| 2010-12-31 | CN¥342.89 Million | +6.04% |
| 2009-12-31 | CN¥323.37 Million | -0.02% |
| 2008-12-31 | CN¥323.43 Million | +6.57% |
| 2007-12-31 | CN¥303.49 Million | +0.93% |
| 2006-12-31 | CN¥300.69 Million | +19.34% |
| 2005-12-31 | CN¥251.96 Million | +12.49% |
| 2004-12-31 | CN¥223.98 Million | +21.78% |
| 2003-12-31 | CN¥183.92 Million | +24.13% |
| 2002-12-31 | CN¥148.17 Million | +11.34% |
| 2001-12-31 | CN¥133.08 Million | +59.61% |
| 2000-12-31 | CN¥83.37 Million | +17.06% |
| 1999-12-31 | CN¥71.23 Million | -8.44% |
| 1998-12-31 | CN¥77.79 Million | -- |